Health Care · Pharmaceuticals · US stock · price as of 16 Oct 2026
Key indicators
Price
$29.58
52-week range
$22.57 – $29.88
Market cap
$168.6B
P/E (trailing)
39.0×
EV / EBITDA
16.6×
Free-cash-flow yield
6.5%
Dividend yield
5.8%
Revenue (last 12 months)
$63.7B
Revenue growth (3y a year)
−14.8%
Operating margin
10.8%
Return on invested capital
4.4%
Net debt / EBITDA
4.1×
Fair value
Blended fair value$15.76 range $15 – $17
Versus priceOvervalued−47% to fair value
Peer multiples
$20.58
Fundamentals-adjusted multiple
$17.11
10-year DCF (market-scaled)
$9.59
Earnings power value (floor, not blended)
$13.82
Model uncertainty
High
X-Ray Score
27/ 100 · High confidence · ahead of 8% of sector peers
Valuation36
Growth4
Profitability30
Financial health24
Dividends50
Five-year price chart navy: price · brown: 200-day average · blue band: fair value range
Executive summary
Pfizer is a global biopharmaceutical company that discovers, develops and supplies medicines and vaccines. Its portfolio includes the pneumococcal vaccine Prevnar, the blood thinner Eliquis, the cancer medicine Ibrance and a COVID vaccine and antiviral treatment, plus products in inflammation and rare disease. It also added cancer medicines through its purchase of Seagen. Customers are wholesalers, hospitals, pharmacies and governments.
Revenue of $63.7 billion over the last twelve months comes from patented medicines and vaccines. Revenue has changed at -14.8% a year across the last three years, a sharp decline. The operating margin is 10.8%, the business earns 4% on the capital invested in it, and net debt is 4.1 times EBITDA. The dividend yield is 5.8%.
StocksXray gives Pfizer Inc an X-Ray Score of 27 out of 100 (high confidence), ahead of 8% of the S&P 500 stocks in its sector. Its strongest lens is dividends (50) and its weakest is growth (4).
Our fair value blend is $15.76 (range $15.02 to $17.17). At $29.58 the stock trades 88% above that blend, so the label is "Overvalued" with high model uncertainty. Fair value is a range, not a price target.
XStocksXray
Pfizer Inc (PFE)
Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months
FY2021
FY2022
FY2023
FY2024
FY2025
Now
Price
$45.72
$40.96
$24.06
$23.53
$23.68
$29.58
Market cap
$261.0B
$234.8B
$137.4B
$134.1B
$135.3B
$168.6B
P/E
11.9×
7.5×
65.0×
16.7×
17.4×
39.0×
EV / revenue
3.4×
2.5×
3.4×
2.9×
3.0×
3.5×
EV / EBITDA
8.9×
6.1×
21.2×
10.3×
11.3×
16.6×
Price / free cash flow
8.7×
9.0×
28.7×
13.6×
14.9×
15.3×
Free-cash-flow yield
11.4%
11.1%
3.5%
7.3%
6.7%
6.5%
Price / book
3.4×
2.5×
1.5×
1.5×
1.6×
2.0×
Dividend yield
3.43%
3.93%
6.86%
7.18%
7.26%
5.81%
Fundamentals checklist ● 2 Good · ● 2 Average · ● 12 Bad · each check graded against the sector
Cash quality
Earnings backed by cash−4.5%Good
Free-cash-flow yield6.5%Good
Risk models
Altman Z score3.1×Average
Piotroski F-Score5 of 9Bad
Growth
EPS growth (3y)−37.1%Bad
Free-cash-flow growth (3y)−29.6%Bad
Revenue growth (3y)−14.8%Bad
Growth consistency60%Bad
Balance sheet
Current ratio1.3×Average
Net debt / EBITDA4.1×Bad
Interest cover2.6×Bad
Valuation
Fair value vs price0.5×Bad
EBIT / EV yield3.1%Bad
Profitability
Return on invested capital4.4%Bad
Operating margin10.8%Bad
Gross profitability23.2%Bad
XStocksXray
Pfizer Inc (PFE)
Financials US$ millions, from SEC filings; last column is the last twelve months
Income statement
FY21
FY22
FY23
FY24
FY25
LTM
Revenue
81,288
101,175
59,553
63,627
62,579
63,696
Gross profit
50,467
66,831
34,599
45,776
46,512
46,612
Operating income
25,602
35,967
3,267
11,114
10,191
6,907
Net income
21,979
31,372
2,119
8,031
7,771
4,332
Diluted EPS ($)
3.85
5.47
0.37
1.41
1.36
0.76
Free cash flow
29,869
26,031
4,793
9,835
9,075
10,985
Gross margin
62.1%
66.1%
58.1%
71.9%
74.3%
73.2%
Operating margin
31.5%
35.5%
5.5%
17.5%
16.3%
10.8%
Net margin
27.0%
31.0%
3.6%
12.6%
12.4%
6.8%
Balance sheet
FY21
FY22
FY23
FY24
FY25
LTM
Total assets
181,476
197,205
226,501
213,396
208,160
201,131
Cash
1,944
416
2,853
1,043
1,142
976
Total debt
37,831
35,444
71,757
63,605
64,638
63,100
Equity
77,201
95,661
89,014
88,203
86,476
85,190
Dividend per share ($)
1.57
1.61
1.65
1.69
1.72
1.72
Revenue and net income US$ billions: navy revenue, teal net income
Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value blends three models and carries a typical error of about 40%, so treat it as a range. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.